Hypoglycemic Agents: all 3,927 studies that test it

Page 25 of 40. Open to participants first (294), then studies with results posted, then the rest; newest registration first within each.

• Simvastatin and Metformin in Chronic PeriodontitisCompletedNCT02372656Phase 2/3
• Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult VolunteersCompletedNCT02371603Phase 1
• Metformin and Simvastatin Use in Bladder CancerStatus unknownNCT02360618Phase 2
• Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP)CompletedNCT02347501Phase 2
• Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized MealCompletedNCT02344992Phase 1
• Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in CombinationCompletedNCT02342067Phase 1
• Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate CancerCompletedNCT02339168Phase 1
• Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination TherapyCompletedNCT02338921Phase 4
• Influence of Gut Hormones on Food Intake After Roux-en-Y Gastric Bypass SurgeryCompletedNCT02336659Not applicable
• Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by SurgeryActive, not recruitingNCT02336087Phase 1
• Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes TrialCompletedNCT02330406Phase 4
• A Comparison of Exenatide and Insulin GlargineCompletedNCT02325960Phase 4
• Effects of Metformin in Pre-frail ElderlyStatus unknownNCT02325245Phase 3
• Primary Prevention Hepatocellular Carcinoma by MetforminTerminatedNCT02319200Phase 3
• Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes ManagementStatus unknownNCT02315287Phase 4
• Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian CancerCompletedNCT02312661Phase 1
• Improving Fibrosis Outcomes With MetforminWithdrawnNCT02306070Phase 2
• The Effect of Multiple Doses of BI 187004 on the Single-dose Pharmacokinetics of Repaglinide and Bupropion in Healthy Male VolunteersCompletedNCT02305901Phase 1
• Effect of Obesity-derived Cytokines on Protein Turnover and Carbohydrate Metabolism in Human Skeletal MuscleCompletedNCT02305069Not applicable
• Intra-Arterial Microdosing: Proof-of-Concept in HumansCompletedNCT02304211Early Phase 1
• Efficacy of Oral Trigonella Foenum-graecum Seed Extract Vs Placebo in Treatment of None Alcoholic Fatty Liver DiseaseCompletedNCT02303314Phase 2/3
• Involvement of Reticulum Endoplasmic Stress in the Physiopathology of Polycystic Ovary SyndromeCompletedNCT02302326Not applicable
• Effects of Sitaglpitin on Endothelial Function During the OGTT in T2DMStatus unknownNCT02301806Phase 4
• Sitagliptin and Brown Adipose TissueCompletedNCT02294084Phase 4
• Platelet Rich Fibrin With 1% Metformin Gel for Treatment of Intrabony DefectsCompletedNCT02283554Phase 2
• Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With MetforminCompletedNCT02280486Phase 4
• Effect of Linagliptin on TRL MetabolismStatus unknownNCT02280174Phase 4
• Trial With Metformin in Women With Polycystic Ovary SyndromeCompletedNCT02280057Phase 4
• A Pilot Study of Metformin Treatment in Patients With Well-differentiated Neuroendocrine TumorsStatus unknownNCT02279758Phase 2
• Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast CancerCompletedNCT02278965Phase 1
• Normal Versus Dual Wave Insulin Bolus for High-protein FoodCompletedNCT02276859Phase 4
• Bioavailability of BI 10773 and Pioglitazone in Healthy Male VolunteersCompletedNCT02276365Phase 1
• Medico-GDM Trial - Metformine to Prevent Gestational Diabetes MellitusCompletedNCT02275845Phase 3
• Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic PatientsTerminatedNCT02274740Phase 2
• 1% Metformin in Moderate and Severe PeriodontitisCompletedNCT02274090Phase 2/3
• Topiramate and Severe ObesityCompletedNCT02273804Phase 3
• Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRIWithdrawnNCT02263677Phase 4
• Effect of Acupuncture to Endothelial Dysfunction Induced by Ischemia-reperfusion InjuryStatus unknownNCT02255006Not applicable
• Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical UnitWithdrawnNCT02250794Phase 4
• Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy SubjectsCompletedNCT02249910Phase 1
• Insulin Bolus Required for High Fat Foods in Type 1 DiabetesCompletedNCT02248454Not applicable
• Effect of Metformin Therapy on Serum Under-carboxylated Osteocalcin Levels in Hyperandrogenic Lean Polycystic Ovarian Syndrome WomenStatus unknownNCT02244567Phase 1
• Topiramate-Phentermine Combinations for Cocaine DependenceCompletedNCT02239913Phase 1
• Enhancement of Brown Adipose Tissue Function Via Chronic Pharmacological TreatmentStatus unknownNCT02236962Not applicable
• Effect of Metformin on Disease Progression in Patients With Cryptogenic Cirrhosis (NASH-related Cirrhosis) With Diabetes or Impaired Glucose Tolerance or Insulin ResistanceCompletedNCT02234440Not applicable
• Drug-drug Interaction Between Digoxin, Furosemide, Metformin, and RosuvastatinCompletedNCT02231931Phase 1
• The Practical Evidence of Antidiabetic Combination Therapy in KoreaCompletedNCT02231021Phase 4
• The Inova Type 2 Diabetes Mellitus StudyWithdrawnNCT02222623Not applicable
• Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)CompletedNCT02222441Phase 1
• Phase 2 Study of DS-8500a in Patients With Type 2 DiabetesCompletedNCT02222350Phase 2
• Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy VolunteersCompletedNCT02221414Phase 1
• Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy VolunteersCompletedNCT02221401Phase 1
• A Trial to Compare the PK and PD of Insulin Lispro Administered Into Different Tissues in Subjects With Diabetes Mellitus Type 1CompletedNCT02221323Phase 2
• Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted ParticipantsCompletedNCT02221180Phase 1
• Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy VolunteersCompletedNCT02220647Phase 1
• Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted ParticipantsCompletedNCT02220218Phase 1
• Comparative Bioavailability Study of Metformin HCl 1000 mg Granules vs Glucophage 1000 mg Film-coated TabletWithdrawnNCT02217670Phase 1
• Glargine Insulin vs.Continuous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN)CompletedNCT02216799Phase 4
• A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 DiabetesCompletedNCT02213146Phase 1/2
• the Pharmacokinetic Profiles of Linagliptin With DW1029MCompletedNCT02212782Phase 1
• Pharmacokinetic Profiles of Metformin With DW1029MCompletedNCT02212756Phase 1
• Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over StudyCompletedNCT02201602Phase 4
• Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on CancerWithdrawnNCT02201381Phase 3
• TOFO Insulin Combination TrialCompletedNCT02201004Phase 4
• Metformin Treatment in Polycystic Ovary Syndrome (PCOS)Status unknownNCT02198417Not applicable
• Neuroprotection of Pioglitazone in Acute Ischemic StrokeTerminatedNCT02195791Phase 2
• Correlation Between Plasma- and Endothelial DPP-4 ActivityCompletedNCT02192853Phase 4
• Insulin Degludec and Symptomatic Nocturnal HypoglycaemiaCompletedNCT02192450Phase 4
• Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated MelanomaTerminatedNCT02190838Phase 2
• Metformin in Psoriatic ArthritisCompletedNCT02188654Not applicable
• PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary SyndromeCompletedNCT02187250Phase 4
• Clinical Trial to Investigate the Pharmacokinetics Drug Interaction Between Metformin and RosuvastatinCompletedNCT02186483Phase 1
• The Effect of Multiple Oral Doses of BI 1356 BS on Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of Simvastatin and on the Pharmacokinetics of Its Metabolite Simvastatin Acid in Healthy Male VolunteersCompletedNCT02183623Phase 1
• Study to Evaluate the Effect of Multiple Doses of Rifampicin on the Multiple-dose Pharmacokinetics of Linagliptin in Healthy VolunteersCompletedNCT02183584Phase 1
• Pharmacokinetics of Single and Multiple Oral Doses of BI 1356 in Healthy Chinese VolunteersCompletedNCT02183532Phase 1
• Bioavailability of BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of BI 1356 BS Alone and Metformin Alone in Healthy Male VolunteersCompletedNCT02183506Phase 1
• Bioavailability of BI 1356 Administered With and Without Food to Healthy Male and Female SubjectsCompletedNCT02183493Phase 1
• Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male SubjectsCompletedNCT02183467Phase 1
• Bioavailability of BI 1356 and Glyburide in Healthy Male and Female VolunteersCompletedNCT02183428Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 DiabetesCompletedNCT02183415Phase 1
• Pharmacokinetics, Safety and Tolerability of Digoxin With or Without Co-administration of BI 1356 in Healthy VolunteersCompletedNCT02183402Phase 1
• Bioavailability of Warfarin After Coadministration With Multiple Doses of BI 1356 Compared to the Bioavailability of Warfarin Alone in Healthy Male VolunteersCompletedNCT02183389Phase 1
• Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy SubjectsCompletedNCT02183376Phase 1
• Bioavailability of BI 1356 After Single Oral Administration Given as Different Tablet Formulation in Healthy Male VolunteersCompletedNCT02183363Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 DiabetesCompletedNCT02183350Phase 1
• Bioavailability of BI 1356 With and Without Co-administration of Pioglitazone and the Bioavailability of Pioglitazone With and Without Coadministration of BI 1356 in Healthy Male and Female VolunteersCompletedNCT02183337Phase 1
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male VolunteersCompletedNCT02183311Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male VolunteersCompletedNCT02183298Phase 1
• Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male VolunteersTerminatedNCT02182401Phase 1
• Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BSCompletedNCT02180503Phase 1
• Effect of Multiple BI 1356 Doses of on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Female Premenopausal SubjectsCompletedNCT02175394Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male SubjectsCompletedNCT02173665Phase 1
• Pharmacokinetics and Pharmacodynamics of Multiple 5 mg Doses of BI 1356 p.o. Given Once Daily Compared to Multiple 2.5 mg Doses Given Twice Daily in Healthy Male and Female VolunteersCompletedNCT02173652Phase 1
• Bioavailability of Combination Tablet BI 1356/Metformin Compared With Single BI 1356 and Metformin Administered Together to Healthy Male and Female SubjectsCompletedNCT02173639Phase 1
• Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes PatientsCompletedNCT02173457Phase 3
• Relative Bioavailability of BI 10773 and Glimepiride in Healthy Male VolunteersCompletedNCT02172261Phase 1
• Relative Bioavailability BI 10773 and Metformin in Healthy Male VolunteersCompletedNCT02172248Phase 1
• Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy VolunteersCompletedNCT02172235Phase 1
• Relative Bioavailability of BI 10773 and Linagliptin in Healthy Male VolunteersCompletedNCT02172222Phase 1
• Bioavailability of BI 10773 and Sitagliptin in Healthy Male VolunteersCompletedNCT02172196Phase 1

← Hypoglycemic Agents overview